跳至主要内容
临床试验/NCT05123885
NCT05123885已完成不适用

Impact Pronostique d'un événement Rythmique Ventriculaire Durant le Port de la LifeVest en Post-infarctus

Mathieu ECHIVARD39 个研究点 分布在 1 个国家目标入组 1,032 人开始时间: 2022年2月2日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
1,032
试验地点
39
主要终点
Rate of rhythmic recurrence defined as the occurrence of a sustained or treated ventricular rhythm disorder (VT or VF) during monitoring of the ICD.

研究概览

简要总结

Sudden death from ventricular arrhythmia is a serious and common complication of myocardial infarction, especially with low left ventricular ejection fraction (LVEF). Implantable cardiac defibrillator (ICD) implantation is currently recommended at three months of optimal medical treatment in patients who have had a myocardial infarction and have a LVEF below 35%. This strategy indeed allows a reduction in mortality while early post-infarction implantation showed no benefit in terms of survival. However, the risk of sudden death at this period is the greatest and the temporary defibrillator vest, marketed under the name LifeVest, is now indicated in the early post-infarction period in patients with LVEF less than 35%. Indeed, the LifeVest would allow a reduction in sudden death of rhythmic origin in the first three months post-infarction. No study has yet investigated the prognostic significance of a ventricular rhythm disorder (ventricular tachycardia [VT] or ventricular fibrillation [VF]) occurring during this early and short (approximately 3 months) particular period of wearing the LifeVest: is this a random event, or is it an event predictive of a rhythmic recurrence? The aim of the study is to assess the association between the occurrence of a sustained ventricular rhythm disorder in the early post-infarction period, during the period of wearing the LifeVest (ventricular episodes detected, treated or not), and the risk of rhythmic recurrence at 12 months.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients who benefited, between the start of 2015 and January 1, 2021, from a LifeVest after a myocardial infarction, followed by the implantation of an ICD before March 1, 2021.

排除标准

  • Patient opposition to the use of their data.

结局指标

主要结局

Rate of rhythmic recurrence defined as the occurrence of a sustained or treated ventricular rhythm disorder (VT or VF) during monitoring of the ICD.

时间窗: 12 months after ICD implantation

次要结局

  • Rate of rhythmic recurrence defined as the occurrence of a sustained or treated ventricular rhythm disorder (VT or VF) during monitoring of the ICD.(Up to 7 years after ICD implantation)
  • Rate of need to set-up left ventricular assist device (LVAD) or heart transplantation.(: 12 months and up to 7 years after ICD implantation)
  • Rate of all-cause death.(12 months and up to 7 years after ICD implantation)
  • Rate of rhythmic storm defined by ACC / AHA / ESC 2006 guidelines (≥3 episodes of VF, sustained VT or appropriate shock in 24 hours).(12 months and up to 7 years after ICD implantation])
  • Rate of hospitalization for heart failure worsening.(12 months and up to 7 years after ICD implantation)
  • Rate of rhythmic recurrence defined as the occurrence of a sustained or treated ventricular rhythm disorder (VT or VF) during monitoring of the ICD, and mortality from any cause.(12 months and up to 7 years after ICD implantation)

研究者

发起方
Mathieu ECHIVARD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Mathieu ECHIVARD

Principal Investigator

Central Hospital, Nancy, France

研究点 (39)

Loading locations...

相似试验